Zimmer Biomet Holdings, Inc. $ZBH Shares Bought by Swedbank AB

Key Points

• Swedbank AB increased its stake in Zimmer Biomet Holdings, Inc. by 77.7% in the second quarter, holding a total of 36,892 shares valued at $3.37 million.
• Zimmer Biomet reported earnings per share of $2.07 for the last quarter, exceeding analyst expectations, with revenue rising 7.0% year-over-year.
• The company declared a quarterly dividend of $0.24 per share, which will be paid on October 31, representing a 1.0% yield.

Swedbank AB grew its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 77.7% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 36,892 shares of the medical equipment provider's stock after acquiring an additional 16,128 shares during the quarter. Swedbank AB's holdings in Zimmer Biomet were worth $3,365,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of the business. OneDigital Investment Advisors LLC purchased a new position in Zimmer Biomet in the first quarter worth about $269,000. Keybank National Association OH lifted its position in shares of Zimmer Biomet by 61.2% during the 1st quarter. Keybank National Association OH now owns 14,315 shares of the medical equipment provider's stock valued at $1,620,000 after buying an additional 5,434 shares in the last quarter. Envestnet Asset Management Inc. lifted its position in shares of Zimmer Biomet by 26.4% during the 1st quarter. Envestnet Asset Management Inc. now owns 316,308 shares of the medical equipment provider's stock valued at $35,800,000 after buying an additional 66,114 shares in the last quarter. Kingswood Wealth Advisors LLC raised its stake in Zimmer Biomet by 20.0% during the 1st quarter. Kingswood Wealth Advisors LLC now owns 2,605 shares of the medical equipment provider's stock valued at $295,000 after purchasing an additional 435 shares during the period. Finally, Polar Asset Management Partners Inc. bought a new stake in Zimmer Biomet during the 1st quarter valued at approximately $6,462,000. 88.89% of the stock is currently owned by institutional investors.

Zimmer Biomet Stock Up 1.8%

Shares of NYSE ZBH traded up $1.81 during mid-day trading on Monday, reaching $101.90. 1,531,577 shares of the company were exchanged, compared to its average volume of 1,336,843. The company has a quick ratio of 0.96, a current ratio of 1.87 and a debt-to-equity ratio of 0.54. The stock has a market cap of $20.19 billion, a price-to-earnings ratio of 12.62, a P/E/G ratio of 2.30 and a beta of 0.68. Zimmer Biomet Holdings, Inc. has a 1 year low of $89.22 and a 1 year high of $114.72. The firm has a 50-day moving average of $100.06 and a 200 day moving average of $99.35.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share for the quarter, beating analysts' consensus estimates of $1.98 by $0.09. The business had revenue of $2.08 billion for the quarter, compared to analyst estimates of $2.06 billion. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.The company's revenue was up 7.0% on a year-over-year basis. During the same period in the prior year, the company earned $2.01 earnings per share. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. On average, research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Tuesday, September 30th will be issued a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 0.9%. The ex-dividend date of this dividend is Tuesday, September 30th. Zimmer Biomet's dividend payout ratio (DPR) is 23.36%.

Insider Buying and Selling

In related news, SVP Lori Winkler sold 1,500 shares of the firm's stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $104.15, for a total transaction of $156,225.00. Following the sale, the senior vice president directly owned 6,833 shares of the company's stock, valued at $711,656.95. This trade represents a 18.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.70% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

ZBH has been the topic of several recent analyst reports. Evercore ISI decreased their target price on Zimmer Biomet from $102.00 to $96.00 and set an "in-line" rating on the stock in a research note on Tuesday, July 8th. UBS Group lifted their target price on Zimmer Biomet from $91.00 to $96.00 and gave the company a "sell" rating in a research note on Friday, August 8th. Raymond James Financial lifted their target price on Zimmer Biomet from $104.00 to $113.00 and gave the company an "outperform" rating in a research note on Friday, August 8th. Rothschild & Co Redburn initiated coverage on Zimmer Biomet in a research note on Thursday. They set a "buy" rating and a $130.00 target price on the stock. Finally, Roth Capital reissued a "buy" rating on shares of Zimmer Biomet in a research note on Thursday, August 7th. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, seven have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, Zimmer Biomet presently has a consensus rating of "Moderate Buy" and an average target price of $113.16.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.